Summit Therapeutics (SMMT) stock falls as the company faces uncertainty in winning U,S, nod for lead drug after mixed data ...

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that ...

The FDA Oncologic Drug Advisory Committee meetings on Tuesday and Wednesday discussed therapies across lymphoma, multiple myeloma, bladder cancer, and prostate cancer.

Swiss healthcare company Roche (RHHBY) on Friday said that the European Medicines Agency’s Committee for Medicinal Products ...

Swiss pharma major Roche (ROG: SIX) has reported updated results from its Phase III STARGLO trial, showing that a ...

Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year follow-up data from the Phase ...

For J&J, there was a positive outcome as the Oncologic Drugs Advisory Committee (ODAC) voted six to two in favour of approval ...

Roche provides update on US FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory DLBCL: Basel Thursday, May 22, 2025, 12:00 Hrs [IST] Roche ...

The recent 8-1 adcom vote against the U.S. applicability of Genentech Inc.’s Starglo trial is being seen as a warning signal expanding beyond the confirmatory trial for Columvi (glofitamab) as a ...

As reported late last year, the AQUILA trial showed that treatment with daratumumab reduced the risk of progression to ...